Acceptance follows resolution of third-party fill/finish manufacturing issues
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Seeking Alpha / 10 hours ago 1 Views
Seeking Alpha / 10 hours ago 1 Views
Acceptance follows resolution of third-party fill/finish manufacturing issues
Comments